[Detection of minimal residual disease after allogeneic bone marrow transplantation in chronic myeloid leukemia]

Zhonghua Xue Ye Xue Za Zhi. 1997 Mar;18(3):140-2.
[Article in Chinese]

Abstract

Objective: To detect minimal residual disease (MRD) after allogeneic bone marrow transplantation (allo-BMT) in chronic myeloid leukemia (CML).

Methods: M-bcr/abl mRNA was assayed by reverse transcriptase polymerase chain reaction (RT-PCR) in bone marrow cells from 46 successfully sibling marrow engrafted CML patients.

Results: About 70% of the patients achieved genetic complete remission in 3 months post allo-BMT. Four patients were M-bcr/abc mRNA positive at 1.5 to 2 months post allo-BMT and turned to be negative at 3 to 9 months post allo-BMT. One patient was still M-bcr/abl(+) after disease-free survival(DFS) for more than 6 years, while another one was M-bcr/abl(-) after DFS for more than 4 years.

Conclusion: RT-PCR is so far the most sensitive method for MRD detection in CML, but its limitation should not be ignored.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Bone Marrow Transplantation*
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery*
  • Male
  • Neoplasm, Residual
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transplantation, Homologous
  • Young Adult